IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.115
AS - Asia 3.205
EU - Europa 1.886
SA - Sud America 738
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 9
Totale 11.987
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.057
SG - Singapore 1.862
UA - Ucraina 835
BR - Brasile 607
CN - Cina 532
DE - Germania 309
HK - Hong Kong 296
FI - Finlandia 281
VN - Vietnam 251
RU - Federazione Russa 163
IE - Irlanda 118
KR - Corea 86
AR - Argentina 74
SE - Svezia 60
IT - Italia 52
TR - Turchia 44
BD - Bangladesh 28
GB - Regno Unito 28
CA - Canada 25
IN - India 23
MX - Messico 20
ID - Indonesia 19
ZA - Sudafrica 14
EC - Ecuador 13
AT - Austria 10
CO - Colombia 9
EU - Europa 9
IQ - Iraq 9
CL - Cile 8
MA - Marocco 8
PY - Paraguay 8
UZ - Uzbekistan 8
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
PK - Pakistan 6
KE - Kenya 5
VE - Venezuela 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
EG - Egitto 4
FR - Francia 4
OM - Oman 4
PE - Perù 4
PL - Polonia 4
SA - Arabia Saudita 4
BG - Bulgaria 3
ES - Italia 3
IL - Israele 3
JP - Giappone 3
KG - Kirghizistan 3
BO - Bolivia 2
CZ - Repubblica Ceca 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
NL - Olanda 2
NP - Nepal 2
RO - Romania 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CR - Costa Rica 1
DJ - Gibuti 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
LV - Lettonia 1
MK - Macedonia 1
NI - Nicaragua 1
QA - Qatar 1
RS - Serbia 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
TJ - Tagikistan 1
TW - Taiwan 1
VC - Saint Vincent e Grenadine 1
Totale 11.987
Salva come PNG Salva come JPEG
Città #
Fairfield 934
Jacksonville 633
Singapore 506
Ashburn 466
Woodbridge 438
Wilmington 369
Seattle 342
Cambridge 329
Houston 316
Chandler 306
Hong Kong 296
Dearborn 284
Beijing 283
Boardman 140
Princeton 134
Dublin 116
Ann Arbor 115
Ho Chi Minh City 109
Seoul 85
San Diego 78
Hefei 71
São Paulo 67
Los Angeles 65
Buffalo 55
Izmir 40
Dallas 39
Hanoi 39
Norwalk 32
Ogden 29
Redondo Beach 26
Santa Clara 26
Udine 26
Kunming 22
New York 22
Rio de Janeiro 17
Belo Horizonte 13
Curitiba 13
Porto Alegre 13
Nanjing 12
Da Nang 11
Brasília 10
Des Moines 10
Mumbai 10
Ottawa 10
Guangzhou 9
Haiphong 9
Hải Dương 9
Nanchang 9
Thái Bình 9
Santo André 8
Turku 8
Campinas 7
Jinan 7
Johannesburg 7
Montreal 7
Chengdu 6
Grafing 6
Ninh Bình 6
Pelotas 6
Brooklyn 5
Chennai 5
Dhaka 5
Guayaquil 5
Juiz de Fora 5
Mexico City 5
Montes Claros 5
Montevideo 5
Munich 5
São João de Meriti 5
Tashkent 5
Thái Nguyên 5
Uberlândia 5
Vienna 5
Atlanta 4
Baku 4
Bauru 4
Biên Hòa 4
Buenos Aires 4
Cape Town 4
Chicago 4
Criciúma 4
Goiânia 4
Helsinki 4
Indaiatuba 4
João Pessoa 4
Lomas de Zamora 4
Medellín 4
Niterói 4
Nuremberg 4
Orem 4
Osasco 4
Quito 4
Recife 4
Ribeirão das Neves 4
Salvador 4
Santiago 4
Stockholm 4
Suzano 4
The Dalles 4
Toronto 4
Totale 7.248
Salva come PNG Salva come JPEG
Nome #
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 270
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 210
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 169
Taxane-induced nail changes: incidence, clinical presentation and outcome 150
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 145
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 134
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 131
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 130
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 129
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 127
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 126
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 124
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 124
Chemotherapy: which drug and when? 122
Determinants of sensitivity and resistance to fluoropyrimidines 121
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 121
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 121
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 121
Bevacizumab plus fluorouracil: the value of being part of a developing story 120
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 118
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 118
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 117
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 117
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 116
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 115
Current controversies in the adjuvant therapy of colon cancer 114
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 112
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 111
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 110
How uniform are postgraduate training programs in medical oncology in the European Union? 109
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 108
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 108
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 107
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 107
Optimal treatment of metastatic colorectal cancer 107
Current strategies to reduce cisplatin toxicity 106
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 105
Fatigue: a main component of anemia symptomatology 104
The potential role of Tomudex in the treatment of advanced colorectal cancer 103
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 103
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 103
Highlights from the 2008 Gastrointestinal Cancers Symposium 103
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 103
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 103
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 103
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 103
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 102
Urgent need for a new staging system in advanced colorectal cancer 102
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 102
Role of oxaliplatin in the treatment of colorectal neoplasms 101
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 101
Irinotecan in combination with new agents 101
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 101
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 99
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 99
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 98
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 98
Current issues in adjuvant treatment of stage II colon cancer 97
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 96
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 96
Tamoxifen-induced total alopecia 96
The medical treatment of advanced colorectal 95
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 95
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 94
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 94
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 92
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 89
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 89
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 88
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 88
Adjuvant treatment of colorectal cancer in the elderly 84
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies 84
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 83
New directions in the treatment of colorectal cancer: a look to the future 83
Clinical aspects of drug resistance 82
Improved therapeutic index of cisplatin with procaine HCl 82
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 81
Biochemical determinants of antineoplastic activity of fluoropyrimidines 80
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 78
THE ROLE OF METHOTREXATE IN THE TREATMENT OF GESTIONAL TROPHOBLASTIC NEOPLASM 77
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 76
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 76
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 75
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 73
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 73
Drug resistant cells as targets for new therapies 71
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 71
The clinical management of early and advanced colorectal cancer 70
The handling of metastatic colorectal cancer 68
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 68
LE ANEMIE 67
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 67
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 66
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 64
Methotrexate resistant cells as target for selective chemotherapy 64
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 64
PROTOCOLLI DI CHEMIOTERAPIA ANTINEOPLASTICA 64
Randomized comparison of. weekly bolus five-fluorouracil with or without leucovorin in metastatic colorectal carcinoma 64
Sequence dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for these interactions 63
Talking Tomudex: introduction 62
Totale 10.121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.977
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.977
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.020 0 0 0 0 0 185 71 207 293 45 173 46
2021/2022868 28 109 14 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024162 29 8 3 3 16 24 1 11 43 0 0 24
2024/20252.497 38 154 207 71 31 63 89 83 180 297 507 777
2025/20262.100 210 518 340 503 459 70 0 0 0 0 0 0
Totale 12.004